{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T21:06:42Z","timestamp":1793394402507,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":29,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No.81902514"],"award-info":[{"award-number":["No.81902514"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noncommunicable Chronic Diseases-National Science and Technology Major Project","award":["2024ZD0520600"],"award-info":[{"award-number":["2024ZD0520600"]}]},{"DOI":"10.13039\/501100004763","name":"Natural Science Foundation of Inner Mongolia Autonomous Region","doi-asserted-by":"publisher","award":["No.2025YQ036"],"award-info":[{"award-number":["No.2025YQ036"]}],"id":[{"id":"10.13039\/501100004763","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Clinical Medicine Plus X-Young Scholars Project, Peking University, the Fundamental Research Funds for the Central Universities","award":["PKU2023LCXQ011"],"award-info":[{"award-number":["PKU2023LCXQ011"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-04444-z","type":"journal-article","created":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T07:32:54Z","timestamp":1769931174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association of clinicopathological characteristics and baseline peripheral blood lymphocyte subsets with efficacy of first-line immunotherapy in advanced gastric cancer"],"prefix":"10.1007","volume":"17","author":[{"given":"Wenfei","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liyang","family":"Mo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyi","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yakun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaotian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,1]]},"reference":[{"issue":"3","key":"4444_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"4444_CR2","doi-asserted-by":"publisher","first-page":"CD004064","DOI":"10.1002\/14651858.CD004064.pub4","volume":"8","author":"AD Wagner","year":"2017","unstructured":"Wagner AD, Syn NL, Moehler M, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2017;8(8):CD004064. https:\/\/doi.org\/10.1002\/14651858.CD004064.pub4.","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"4444_CR3","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57. https:\/\/doi.org\/10.1186\/s13045-023-01451-3.","journal-title":"J Hematol Oncol"},{"issue":"4suppl","key":"4444_CR4","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.2025.43.4_suppl.392","volume":"43","author":"L Shen","year":"2025","unstructured":"Shen L, Bai Y, Lin X, et al. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC\/GEJC\/EAC): 5-year (y) follow-up of Chinese Pts from checkmate 649. J Clin Oncol. 2025;43(4suppl):392\u2013392. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.392.","journal-title":"J Clin Oncol"},{"issue":"9","key":"4444_CR5","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 Inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358. https:\/\/doi.org\/10.1038\/s41591-018-0101-z.","journal-title":"Nat Med"},{"issue":"10","key":"4444_CR6","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21(10):1353\u201365. https:\/\/doi.org\/10.1016\/S1470-2045(20)30445-9.","journal-title":"Lancet Oncol"},{"issue":"1","key":"4444_CR7","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","volume":"17","author":"X Chong","year":"2024","unstructured":"Chong X, Madeti Y, Cai J, et al. Recent developments in immunotherapy for Gastrointestinal tract cancers. J Hematol Oncol. 2024;17(1):65. https:\/\/doi.org\/10.1186\/s13045-024-01578-x.","journal-title":"J Hematol Oncol"},{"issue":"5","key":"4444_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.annonc.2021.02.006","volume":"32","author":"DJ McGrail","year":"2021","unstructured":"McGrail DJ, Pilie PG, Rashid NU, et al. High tumor mutation burden fails to predict immune checkpoint Blockade response across all cancer types. Ann Oncol. 2021;32(5):661\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2021.02.006.","journal-title":"Ann Oncol"},{"issue":"5","key":"4444_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1001\/jamaoncol.2020.7684","volume":"7","author":"C Valero","year":"2021","unstructured":"Valero C, Lee M, Hoen D, et al. Response rates to Anti-PD-1 immunotherapy in Microsatellite-Stable solid tumors with 10 or more mutations per megabase. JAMA Oncol. 2021;7(5):739\u201343. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7684.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4444_CR10","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1038\/s41591-024-03398-5","volume":"31","author":"SK Yoo","year":"2025","unstructured":"Yoo SK, Fitzgerald CW, Cho BA, et al. Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data. Nat Med. 2025;31(3):869\u201380. https:\/\/doi.org\/10.1038\/s41591-024-03398-5.","journal-title":"Nat Med"},{"issue":"6","key":"4444_CR11","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","volume":"7","author":"J Chao","year":"2021","unstructured":"Chao J, Fuchs CS, Shitara K, et al. Assessment of pembrolizumab therapy for the treatment of microsatellite Instability-High gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials. JAMA Oncol. 2021;7(6):895\u2013902. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0275.","journal-title":"JAMA Oncol"},{"issue":"3","key":"4444_CR12","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00262-021-03018-y","volume":"71","author":"DH Kang","year":"2022","unstructured":"Kang DH, Chung C, Sun P, et al. Circulating regulatory T cells predict efficacy and atypical responses in lung cancer patients treated with PD-1\/PD-L1 inhibitors. Cancer Immunol Immunother. 2022;71(3):579\u201388. https:\/\/doi.org\/10.1007\/s00262-021-03018-y.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"4444_CR13","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2217\/imt-2020-0068","volume":"13","author":"C Liu","year":"2021","unstructured":"Liu C, Wang Y, Li S, et al. Early change in peripheral CD4(+) T cells associated with clinical outcomes of immunotherapy in Gastrointestinal cancer. Immunotherapy. 2021;13(1):55\u201366. https:\/\/doi.org\/10.2217\/imt-2020-0068.","journal-title":"Immunotherapy"},{"issue":"15","key":"4444_CR14","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.7150\/jca.88101","volume":"14","author":"Q Xie","year":"2023","unstructured":"Xie Q, Hu C, Luo C. The alterations in peripheral lymphocyte subsets predict the efficacy and prognosis of immune checkpoint inhibitors in hepatocellular carcinoma. J Cancer. 2023;14(15):2946\u201355. https:\/\/doi.org\/10.7150\/jca.88101.","journal-title":"J Cancer"},{"issue":"11","key":"4444_CR15","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Yanez P, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395. https:\/\/doi.org\/10.1016\/S1470-2045(23)00515-6.","journal-title":"Lancet Oncol"},{"issue":"3suppl","key":"4444_CR16","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1200\/JCO.2024.42.3_suppl.306","volume":"42","author":"K Shitara","year":"2024","unstructured":"Shitara K, Moehler MH, Ajani JA, et al. Nivolumab (NIVO)\u2009+\u2009chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): 4 year (yr) follow-up of checkmate 649. J Clin Oncol. 2024;42(3suppl):306\u2013306. https:\/\/doi.org\/10.1200\/JCO.2024.42.3_suppl.306.","journal-title":"J Clin Oncol"},{"issue":"21","key":"4444_CR17","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1001\/jama.2023.19918","volume":"330","author":"J Xu","year":"2023","unstructured":"Xu J, Jiang H, Pan Y, et al. Sintilimab plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: the ORIENT-16 randomized clinical trial. JAMA. 2023;330(21):2064\u201374. https:\/\/doi.org\/10.1001\/jama.2023.19918.","journal-title":"JAMA"},{"issue":"4","key":"4444_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1093\/gastro\/goy045","volume":"7","author":"Q Huang","year":"2019","unstructured":"Huang Q, Qin H, Xiao J, et al. Association of tumor differentiation and prognosis in patients with rectal cancer undergoing neoadjuvant chemoradiation therapy. Gastroenterol Rep (Oxf). 2019;7(4):283\u201390. https:\/\/doi.org\/10.1093\/gastro\/goy045.","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"19","key":"4444_CR19","doi-asserted-by":"publisher","first-page":"6627","DOI":"10.1002\/cam4.4195","volume":"10","author":"LY Lee","year":"2021","unstructured":"Lee LY, Lin CY, Cheng NM, et al. Poor tumor differentiation is an independent adverse prognostic variable in patients with locally advanced oral cavity cancer\u2013Comparison with pathological risk factors according to the NCCN guidelines. Cancer Med. 2021;10(19):6627\u201341. https:\/\/doi.org\/10.1002\/cam4.4195.","journal-title":"Cancer Med"},{"issue":"4","key":"4444_CR20","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/nri1806","volume":"6","author":"W Zou","year":"2006","unstructured":"Zou W, Regulatory T. cells, tumour immunity and immunotherapy. Nat Rev Immunol. 2006;6(4):295\u2013307. https:\/\/doi.org\/10.1038\/nri1806.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"4444_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s12876-024-03168-0","volume":"24","author":"X Wang","year":"2024","unstructured":"Wang X, Liu X, Dai H, et al. Association of lymphocyte subsets with the efficacy and prognosis of PD\u20131 inhibitor therapy in advanced gastric cancer: results from a monocentric retrospective study. BMC Gastroenterol. 2024;24(1):113. https:\/\/doi.org\/10.1186\/s12876-024-03168-0.","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"4444_CR22","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1038\/s41591-025-03575-0","volume":"31","author":"K Shitara","year":"2025","unstructured":"Shitara K, Janjigian YY, Ajani J, et al. Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial. Nat Med. 2025;31(5):1519\u201330. https:\/\/doi.org\/10.1038\/s41591-025-03575-0.","journal-title":"Nat Med"},{"key":"4444_CR23","doi-asserted-by":"publisher","first-page":"715901","DOI":"10.3389\/fcell.2021.715901","volume":"9","author":"LE Sjaastad","year":"2021","unstructured":"Sjaastad LE, Owen DL, Tracy SI, et al. Phenotypic and functional diversity in regulatory T cells. Front Cell Dev Biol. 2021;9:715901. https:\/\/doi.org\/10.3389\/fcell.2021.715901.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"4444_CR24","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12967-024-05104-y","volume":"22","author":"Y Li","year":"2024","unstructured":"Li Y, Zhang C, Jiang A, et al. Potential anti-tumor effects of regulatory T cells in the tumor microenvironment: a review. J Transl Med. 2024;22(1):293. https:\/\/doi.org\/10.1186\/s12967-024-05104-y.","journal-title":"J Transl Med"},{"key":"4444_CR25","doi-asserted-by":"publisher","first-page":"684098","DOI":"10.3389\/fonc.2021.684098","volume":"11","author":"DR Principe","year":"2021","unstructured":"Principe DR, Chiec L, Mohindra NA, et al. Regulatory T-Cells as an emerging barrier to immune checkpoint Inhibition in lung cancer. Front Oncol. 2021;11:684098. https:\/\/doi.org\/10.3389\/fonc.2021.684098.","journal-title":"Front Oncol"},{"key":"4444_CR26","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.3389\/fimmu.2018.02374","volume":"9","author":"E Gianchecchi","year":"2018","unstructured":"Gianchecchi E, Fierabracci A. Inhibitory receptors and pathways of lymphocytes: the role of PD-1 in Treg development and their involvement in autoimmunity onset and cancer progression. Front Immunol. 2018;9:2374. https:\/\/doi.org\/10.3389\/fimmu.2018.02374.","journal-title":"Front Immunol"},{"issue":"13","key":"4444_CR27","doi-asserted-by":"publisher","first-page":"3015","DOI":"10.1084\/jem.20090847","volume":"206","author":"LM Francisco","year":"2009","unstructured":"Francisco LM, Salinas VH, Brown KE, et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med. 2009;206(13):3015\u201329. https:\/\/doi.org\/10.1084\/jem.20090847.","journal-title":"J Exp Med"},{"key":"4444_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61091614","author":"P Peker","year":"2025","unstructured":"Peker P, Ge\u00e7gel A, \u00d6zkan O, et al. Systemic immune-inflammation index as a prognostic marker in gastric and gastroesophageal junction cancers receiving perioperative FLOT therapy. Medicina. 2025. https:\/\/doi.org\/10.3390\/medicina61091614.","journal-title":"Medicina"},{"issue":"1","key":"4444_CR29","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/s41598-024-84890-3","volume":"15","author":"J Su","year":"2025","unstructured":"Su J, Li Y, Tan S, et al. Pretreatment neutrophil-to-lymphocyte ratio is associated with immunotherapy efficacy in patients with advanced cancer: a systematic review and meta-analysis. Sci Rep. 2025;15(1):446. https:\/\/doi.org\/10.1038\/s41598-024-84890-3.","journal-title":"Sci Rep"},{"key":"4444_CR30","doi-asserted-by":"publisher","first-page":"1070019","DOI":"10.3389\/fonc.2023.1070019","volume":"13","author":"S Zhang","year":"2023","unstructured":"Zhang S, Qiu C, Yu H, et al. Prognostic value of neutrophil to lymphocyte ratio in gastric cancer patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Front Oncol. 2023;13:1070019. https:\/\/doi.org\/10.3389\/fonc.2023.1070019.","journal-title":"Front Oncol"},{"issue":"6","key":"4444_CR31","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/gastro\/goab032","volume":"9","author":"DY Ruan","year":"2021","unstructured":"Ruan DY, Chen YX, Wei XL, et al. Elevated peripheral blood neutrophil-to-lymphocyte ratio is associated with an immunosuppressive tumour microenvironment and decreased benefit of PD-1 antibody in advanced gastric cancer. Gastroenterol Rep (Oxf). 2021;9(6):560\u201370. https:\/\/doi.org\/10.1093\/gastro\/goab032.","journal-title":"Gastroenterol Rep (Oxf)"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-04444-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-04444-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T09:57:22Z","timestamp":1772445442000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-04444-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,1]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4444"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-04444-z","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,1]]},"assertion":[{"value":"17 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committee of Peking University Cancer Hospital (Ethics approval number: 2022KT171). The procedures used in this study adhere to the tenets of the Declaration of Helsinki. Informed consent was waived due to the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"379"}}